Intellectual Ventures Laboratory, 1555 132(nd) Ave. NE, Bellevue, WA 98005, USA.
Intellectual Ventures Laboratory, 1555 132(nd) Ave. NE, Bellevue, WA 98005, USA.
Int J Infect Dis. 2014 Jan;18:4-13. doi: 10.1016/j.ijid.2013.09.005. Epub 2013 Oct 22.
To examine forces that drive vaccination policy to eradicate wild- and vaccine-derived poliovirus, and to focus on the efficacy of vaccines to support decision-making and further research.
We searched PubMed and Ovid databases for English-language publications, without date restrictions. We also collected references from major reviews on polio vaccine immunogenicity or protection. We conducted a meta-analysis of human immunity to polio infections using multiple non-linear regression, and built a database from a broad (but not systematic) set of polio vaccine studies (46 studies, >10000 subjects).
The outcome was an immunological model representative of many different datasets. Parameters measured immunogenicity to both humoral and mucosal immune compartments for Salk and Sabin vaccines. The immunity model was more highly correlated with the data than a simpler per-dose efficacy model.
The model offers new insights for immunization policy. We measured the mucosal immunogenicity of IPV to a precision that is useful in decision-making for end-game polio immunization policies.
探讨推动消灭野生和疫苗衍生脊髓灰质炎病毒的疫苗接种政策的驱动力,并重点关注疫苗的功效,以支持决策和进一步的研究。
我们检索了 PubMed 和 Ovid 数据库中的英文文献,不设日期限制。我们还从脊髓灰质炎疫苗免疫原性或保护作用的主要综述中收集了参考文献。我们使用多种非线性回归对人类对脊髓灰质炎感染的免疫进行了荟萃分析,并从广泛(但非系统)的一组脊髓灰质炎疫苗研究(46 项研究,超过 10000 名受试者)中构建了一个数据库。
该结果是一个代表许多不同数据集的免疫模型。该模型测量了 Salk 和 Sabin 疫苗对体液和黏膜免疫区室的免疫原性。该免疫模型与数据的相关性高于更简单的每剂量疗效模型。
该模型为免疫政策提供了新的见解。我们以对终结脊髓灰质炎免疫政策决策有用的精度测量了 IPV 的黏膜免疫原性。